Yasuaki Shimizu

1.1k total citations
39 papers, 901 citations indexed

About

Yasuaki Shimizu is a scholar working on Molecular Biology, Physiology and Immunology. According to data from OpenAlex, Yasuaki Shimizu has authored 39 papers receiving a total of 901 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 17 papers in Physiology and 12 papers in Immunology. Recurrent topics in Yasuaki Shimizu's work include Asthma and respiratory diseases (13 papers), Phosphodiesterase function and regulation (8 papers) and Chemokine receptors and signaling (5 papers). Yasuaki Shimizu is often cited by papers focused on Asthma and respiratory diseases (13 papers), Phosphodiesterase function and regulation (8 papers) and Chemokine receptors and signaling (5 papers). Yasuaki Shimizu collaborates with scholars based in Japan, United States and Slovakia. Yasuaki Shimizu's co-authors include Kenji Sudo, Keiko Ohga, Nobuaki Takeshita, Jun Ishikawa, Koichiro Takahashi, Ryuichi Takezawa, Yukinori Nagakura, Satoshi Yamamoto, Hiroshi Suzuki and Miki Kobayashi and has published in prestigious journals such as Nature, Nucleic Acids Research and The Journal of Immunology.

In The Last Decade

Yasuaki Shimizu

39 papers receiving 854 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yasuaki Shimizu Japan 21 359 262 160 118 118 39 901
José G. Ferraz Canada 17 416 1.2× 290 1.1× 248 1.6× 64 0.5× 108 0.9× 25 1.6k
Chikako Watanabe Japan 23 350 1.0× 141 0.5× 302 1.9× 50 0.4× 158 1.3× 72 1.3k
Adriano L.S. Souza Brazil 19 178 0.5× 144 0.5× 225 1.4× 98 0.8× 91 0.8× 24 875
Ohn A. Chow United States 7 240 0.7× 166 0.6× 505 3.2× 79 0.7× 57 0.5× 10 897
Christina L. Hirota Canada 16 295 0.8× 94 0.4× 285 1.8× 56 0.5× 99 0.8× 23 1.1k
Olivier Morteau United States 17 247 0.7× 177 0.7× 473 3.0× 41 0.3× 205 1.7× 18 1.2k
Neerad C. Mishra United States 20 518 1.4× 198 0.8× 125 0.8× 234 2.0× 55 0.5× 29 1.1k
Barbara J. Nelson United States 16 282 0.8× 110 0.4× 218 1.4× 148 1.3× 206 1.7× 21 1.1k
Hyung‐Joon Kwon South Korea 13 395 1.1× 159 0.6× 347 2.2× 53 0.4× 115 1.0× 18 942
André Klein Brazil 20 359 1.0× 300 1.1× 303 1.9× 105 0.9× 93 0.8× 50 1.4k

Countries citing papers authored by Yasuaki Shimizu

Since Specialization
Citations

This map shows the geographic impact of Yasuaki Shimizu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yasuaki Shimizu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yasuaki Shimizu more than expected).

Fields of papers citing papers by Yasuaki Shimizu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yasuaki Shimizu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yasuaki Shimizu. The network helps show where Yasuaki Shimizu may publish in the future.

Co-authorship network of co-authors of Yasuaki Shimizu

This figure shows the co-authorship network connecting the top 25 collaborators of Yasuaki Shimizu. A scholar is included among the top collaborators of Yasuaki Shimizu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yasuaki Shimizu. Yasuaki Shimizu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Morikawa, Noriyuki, Yasuko Kato, Nobuaki Takeshita, & Yasuaki Shimizu. (2022). Pharmacological characterization of AS2690168, a novel small molecule RANKL signal transduction inhibitor. European Journal of Pharmacology. 924. 174941–174941. 4 indexed citations
2.
Nagakura, Yukinori, Tomonari Watabiki, Tohru Ozawa, et al.. (2013). Systemic administration of 5-HT2C receptor agonists attenuates muscular hyperalgesia in reserpine-induced myalgia model. Pharmacology Biochemistry and Behavior. 108. 8–15. 28 indexed citations
3.
Nagakura, Yukinori, Masayasu Takahashi, Takahisa Noto, et al.. (2011). Different pathophysiology underlying animal models of fibromyalgia and neuropathic pain: Comparison of reserpine-induced myalgia and chronic constriction injury rats. Behavioural Brain Research. 226(1). 242–249. 40 indexed citations
4.
Takeshita, Nobuaki, et al.. (2011). Alleviating Effects of AS1892802, a Rho Kinase Inhibitor, on Osteoarthritic Disorders in Rodents. Journal of Pharmacological Sciences. 115(4). 481–489. 20 indexed citations
5.
Kobayashi, Miki, Satoshi Kubo, Masahiro Iwata, et al.. (2011). ASP3258, an orally active potent phosphodiesterase 4 inhibitor with low emetic activity. International Immunopharmacology. 11(6). 732–739. 24 indexed citations
6.
Kubo, Satoshi, Miki Kobayashi, Masahiro Iwata, et al.. (2011). Disease-modifying effect of ASP3258, a novel phosphodiesterase type 4 inhibitor, on subchronic cigarette smoke exposure-induced lung injury in guinea pigs. European Journal of Pharmacology. 659(1). 79–84. 16 indexed citations
7.
Hatori, Chie, et al.. (2010). Antinociceptive Effects of AS1892802, a Novel Rho Kinase Inhibitor, in Rat Models of Inflammatory and Noninflammatory Arthritis. Journal of Pharmacology and Experimental Therapeutics. 334(3). 955–963. 31 indexed citations
8.
Yamamoto, Hiroko, et al.. (2010). Sustained Analgesic Effect of the Rho Kinase Inhibitor AS1892802 in Rat Models of Chronic Pain. Journal of Pharmacological Sciences. 114(1). 119–122. 10 indexed citations
9.
Kodama, Eiichi, Masaya Orita, Naoyuki Masuda, et al.. (2008). Binding Modes of Two Novel Non-Nucleoside Reverse Transcriptase Inhibitors, YM-215389 and YM-228855, to HIV Type-1 Reverse Transcriptase. Antiviral chemistry & chemotherapy. 19(3). 133–141. 3 indexed citations
10.
Saita, Yuji, Mitsuhiro Kondo, & Yasuaki Shimizu. (2007). Species selectivity of small-molecular antagonists for the CCR5 chemokine receptor. International Immunopharmacology. 7(12). 1528–1534. 19 indexed citations
11.
Saita, Yuji, Eiichi Kodama, Masaya Orita, et al.. (2006). Structural Basis for the Interaction of CCR5 with a Small Molecule, Functionally Selective CCR5 Agonist. The Journal of Immunology. 177(5). 3116–3122. 28 indexed citations
12.
Yamamoto, Satoshi, et al.. (2006). The effects of a novel phosphodiesterase 7A and -4 dual inhibitor, YM-393059, on T-cell-related cytokine production in vitro and in vivo. European Journal of Pharmacology. 541(1-2). 106–114. 22 indexed citations
13.
Saita, Yuji, Mitsuhiro Kondo, Takahiro Miyazaki, Noboru Yamaji, & Yasuaki Shimizu. (2005). Transgenic mouse expressing human CCR5 as a model for in vivo assessments of human selective CCR5 antagonists. European Journal of Pharmacology. 518(2-3). 227–233. 5 indexed citations
14.
Sudo, Kenji, et al.. (2005). YM-53403, a unique anti-respiratory syncytial virus agent with a novel mechanism of action. Antiviral Research. 65(2). 125–131. 57 indexed citations
15.
Suzuki, Keiko, Tatsuaki Morokata, Koichiro Morihira, et al.. (2005). In vitro and in vivo characterization of a novel CCR3 antagonist, YM-344031. Biochemical and Biophysical Research Communications. 339(4). 1217–1223. 27 indexed citations
16.
Sudo, Kenji, et al.. (2005). High-Throughput Screening of Low Molecular Weight NS3-NS4A Protease Inhibitors Using a Fluorescence Resonance Energy Transfer Substrate. Antiviral chemistry & chemotherapy. 16(6). 385–392. 13 indexed citations
17.
Inoue, Hiroshi, Hitoshi Sakashita, Yasuaki Shimizu, et al.. (1998). Expression of a Hepatitis C Virus NS3 Protease–NS4A Fusion Protein inEscherichia coli. Biochemical and Biophysical Research Communications. 245(2). 478–482. 7 indexed citations
18.
Sudo, Kenji, Hiroshi Inoue, Yasuaki Shimizu, et al.. (1996). Establishment of an in vitro assay system for screening hepatitis C virus protease inhibitors using high performance liquid chromatography. Antiviral Research. 32(1). 9–18. 34 indexed citations
19.
Shimizu, Yasuaki, et al.. (1993). Agonist-stimulated Cl− efflux from human neutrophils. Biochemical Pharmacology. 45(9). 1743–1751. 25 indexed citations
20.
Shimizu, Yasuaki, et al.. (1988). Molecular cloning and expression in Escherichia coli of the cDNA coding for rat lipocortin I (calpactin II). Gene. 65(1). 141–147. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by José G. Ferraz Breakdown of academic impact, for papers by Chikako Watanabe Breakdown of academic impact, for papers by Adriano L.S. Souza Breakdown of academic impact, for papers by Ohn A. Chow Breakdown of academic impact, for papers by Christina L. Hirota Breakdown of academic impact, for papers by Olivier Morteau Breakdown of academic impact, for papers by Neerad C. Mishra Breakdown of academic impact, for papers by Barbara J. Nelson Breakdown of academic impact, for papers by Hyung‐Joon Kwon Breakdown of academic impact, for papers by André Klein
Rankless by CCL
2026